Navigation Links
CRESTOR(R) Reduced Risk of Cardiovascular Events in Elderly Patients in New Analysis of Jupiter
Date:8/31/2009

BARCELONA, Spain, Aug. 31 /PRNewswire/ -- A new analysis from the JUPITER study showed that CRESTOR((R)) (rosuvastatin calcium) 20mg reduced the composite primary end point of major cardiovascular (CV) events (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by 39% (p<0.001), compared to placebo, in elderly patients with LDL-C less than 130 mg/dL and elevated high-sensitivity C-reactive protein (hsCRP). This analysis was conducted in 5,695 patients aged 70 years or older. The results from this analysis are consistent with the CV risk reduction seen across all patients taking rosuvastatin in the primary JUPITER analysis. These data were presented today at the European Society of Cardiology (ESC) meeting in Barcelona, Spain.

Additional results from this analysis showed that treatment with CRESTOR:

  • Reduced the combined risk of cardiovascular death, heart attack and stroke by nearly 40% (p=0.004 vs. placebo)
  • Reduced the risk of heart attack by 45% (p=0.046 vs. placebo) and of stroke by 45% (p=0.023 vs. placebo)
  • Reduced the need for hospitalization for arterial revascularization or unstable angina by 49% (p=0.003 vs. placebo)
  • Treatment effects, relative to placebo, were generally comparable in both the elderly (aged 70 or older) and younger patient groups

"In this study, treatment with CRESTOR significantly reduced the risk of major cardiovascular events in elderly patients," said Alex Gold, MD, Executive Director of Clinical Development for CRESTOR, AstraZeneca US. "CRESTOR was also well tolerated in patients aged 70 and older, consistent with the other patients in the study."

AstraZeneca (NYSE: AZN) filed a regulatory subm
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
4. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
5. CRESTOR(R) Reduced Risk of Blood Clots in the Veins
6. CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis
7. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
8. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
9. Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014  With a vision to ... medications, a Global Pharmaceutical and Biotech manufacturer selects ... and turnkey solution to protect their animal health ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... serialized and aggregated by the Xyntek and Antares ...
(Date:10/22/2014)... Calif. , Oct. 21, 2014 Influenza will ... flu-associated deaths in the United States ... viruses are thought to spread is from person to person ... Ebola has a serve way of death, but kills much ... Ebola is also done by human fluids including sweat, saliva, ...
(Date:10/22/2014)... Va. and AUSTIN, Texas ... Inc. and PureMHC LLC today announced they have ... develop novel antibody-based immunotherapies designed to target cancers. ... of phosphorylated peptides displayed on the surfaces of ... phosphopeptide tumor targets (PTTs), derived from proteins that ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
... Calif., Aug. 19 Burton Medical, Inc., the leader ... Burton LE-35  to deliver superior illumination, improved reach, and ...  The 35-watt LE-35 provides two to five times more ... improving efficacy and visibility.  This task light provides illuminance ...
... Md., Aug. 19 Novavax, Inc. (Nasdaq: NVAX ... press briefing by U.S. Health and Human Services Secretary Kathleen ... plan to accelerate the development of drugs and vaccines to ... statement of support for the plan,s five key initiatives: ...
Cached Medicine Technology:NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures 2NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures 3
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. ... in vitro fertilization (IVF) -- the incubation of embryos in ... device inside the vagina, new research suggests. Scientists from ... an INVOcell, might sharply cut costs for pricey IVF procedures ... accessible to those who don,t live near big-city assisted reproduction ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... October 20, 2014 ASCNYC (ascnyc.org) ... that helps New Yorkers living with HIV/AIDS and ... health, housing, recovery and self-sufficiency. Each year, ASCNYC ... local community through their tireless efforts. , ... Shapses , has been selected as this year’s ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ... platform to think outside the bra. She doesn’t try to ... raise awareness about women’s other lady parts. , "We have ... the color pink and everybody knows what you’re talking about,” ... it has not been won when it comes to gynecologic ...
Breaking Medicine News(10 mins):Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3
... Ind., May 7 Conseco, Inc. (NYSE: ... regulators and two of,its insurance subsidiaries: Conseco Senior ... Company. The settlement concludes a,multistate market conduct examination ... to long-term care claims practices and,procedures, complaint handling, ...
... May 7 Yesterday H. Con.,Res. 342 was introduced ... opposing the Food and Drug Administration,s (FDA) decision to,restrict ... by women to alleviate the symptoms of menopause. The ... pharmacies in January asking them to,cease and desist with ...
... were missed, more doses taken on time , , WEDNESDAY, May ... are less likely to miss doses when reminded by an ... and announces the number of pills to take and how ... was funded by the National Institute on Aging, was presented ...
... AFL ) announced today that it will webcast its annual Financial,Analysts ... operations in Japan and in the United States as well as ... as,follows:, Wednesday, May 14, 2008 8:00 p.m. ... Daniel P. Amos, Chairman & ...
... May 7 Amneal Pharmaceuticals is pleased,to announce ... Primidone,Tablets (50/250mg), Cyclobenzaprine Tablets (10mg) and Demeclocycline,Tablets (150/300mg) ... products,were filed during 2007 using the FDA,s evolutionary ... months., Demeclocycline HCl Tablets USP, in strengths ...
... NHS Choices ( http://www.nhs.uk ), the new,digital ,front ... Well bundle aimed to,help people stay healthy during ... information, the Live Well Travel health guide,( http://www.nhs.uk/livewell/travelhealth/Pages/Travelhealthhome.aspx ... and provides them,with clinically approved guidance to help ...
Cached Medicine News:Health News:Conseco Reaches Settlement of Multistate Market Conduct Examination 2Health News:Electronic Pillbox Helps Seniors Stick to Drug Regimens 2Health News:Electronic Pillbox Helps Seniors Stick to Drug Regimens 3Health News:Aflac Incorporated to Webcast 2008 Financial Analysts Briefing 2Health News:Aflac Incorporated to Webcast 2008 Financial Analysts Briefing 3Health News:Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format 2
Multispot HIV-1/HIV-2 is a rapid indirect EIA using recombinant and peptide antigens for simultaneous detection and differentiation of anti-HIV-1 and anti-HIV-2 antibodies in human serum or plasma....
Bio-Rad's Genetic Systems™ HBsAg EIA 3.0 screening and confirmatory assays offer outstanding sensitivity and early detection of HBV infection, helping to meet your testing criteria....
The most compact revolutionary innovation in hematology. 3 Part DIFF + CRP measurement on whole blood....
... Evolis™ is a self contained microplate ... based EIA assays. The system is dedicated ... encountered in todays busy laboratory. The system ... of EIA assays that satisfy their microplate ...
Medicine Products: